EWA
NRIX icon

EP Wealth Advisors’s Nurix Therapeutics NRIX Stock Holding History

EP Wealth Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
+8,816
New +$150K ﹤0.01% 1480
2025
Q1 		– Sell
-10,815
Closed -$204K – 1345
2024
Q4 		$204K Buy
10,815
+122
+1% +$2.8K ﹤0.01% 1072
2024
Q3 		$240K Buy
+10,693
New +$242K ﹤0.01% 958
2022
Q1 		– Sell
-8,333
Closed -$241K – 656
2021
Q4 		$241K Buy
+8,333
New +$253K 0.01% 502

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EP Wealth Advisors's NRIX Position: Q2 2026 in Review

EP Wealth Advisors opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 8,816 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #1480 among its holdings. This is a return to the name: EP Wealth Advisors previously reported a position in NRIX as recently as Q4 2024.

EP Wealth Advisors first reported a position in NRIX in Q4 2021 and has held it in 4 quarters since. The position peaked at $241K in Q4 2021. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • EP Wealth Advisors held 8,816 shares of Nurix Therapeutics worth $214K as of Q2 2026.
  • Nurix Therapeutics was a new EP Wealth Advisors position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of EP Wealth Advisors's portfolio in Q2 2026, its #1480 holding.
  • EP Wealth Advisors first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • EP Wealth Advisors's Nurix Therapeutics position peaked at $241K in Q4 2021.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.